AGR2

Across TCGA pan-cancer cohorts, AGR2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AGR2 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGR2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where AGR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.266	1.000	.001	69	view →
PDAC	DFS	Median	II,III,IV	0.503	0.287	<.001	57	view →
CCRCC	OS	Tertile	All	0.946	0.739	.008	42	view →
HNSC	DFS	Tertile	III,IV	0.501	0.773	.010	14	view →
UCEC	DFS	Median	All	0.957	0.850	.020	4	view →
GBM	DFS	Median	All	0.261	0.485	.028	2	view →
LSCC	DFS	Median	II,III,IV	0.867	0.963	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AGR2–LUAD (OS)

Open the LUAD breakdown →